ChemoCentryx Competitors, Revenue, Alternatives and Pricing

Claim your profile


Total Funding:N/A
Lead Investor(s):N/A

City Ranking

Industry Ranking

State Ranking

Growjo 10k Ranking

Employee Data

  • ChemoCentryx has 177 Employees.(?)
  • ChemoCentryx grew their employee count by 45% last year.
  • ChemoCentryx currently has 1 job openings.

ChemoCentryx, Inc. discovers, develops and commercializes novel small molecule medicines for autoimmune diseases, inflammatory disorders, cancer and infectious disease. Traficet-EN(TM), the company's orally active drug for inflammatory bowel disease, will enter clinical trials in 2003. Other products include an orally active development candidate for rheumatoid arthritis and multiple sclerosis, and emerging drug candidates for cancer and cardiopulmonary inflammation. Another drug, T487, resulted from a ChemoCentryx discovery program and is expected to enter Phase II clinical trials for psoriasis in 2003 with partner Tularik Inc. Leveraging its leadership in chemokine-based drug discovery, ChemoCentryx focuses on new classes of orally active small molecules to selectively inhibit activity of the chemokine system, the "master regulator" of immune response. Based in San Carlos, California, ChemoCentryx is privately held.

keywords:Biotechnology, Healthcare